Aminoglycosides such as streptomycin or gentamycin are employed to treat stubborn infections. In México, tuberculosis patients are successfully treated with 1 g/day for over 6 months. Ototoxicity is often seen as a consequence of prolonged treatment with aminoglycosides. In young people STP damages the vestibule of the ear; in elder patients it diminishes hearing and balance. These effects are due to streptidine, a metabolite of STP produced in elder patients and detected in blood by liquid chromatography. On occasion, sudden deafness is established after only a short treatment period as the result of the presence of a single nucleotide mutation in the mitochondrial 12S rRNA gene. In patients with this polymorphism, aminoglycosides produce a stereotypic conformation similar to the bacterial 16S rRNA thus inhibiting the synthesis of proteins. Many aminoglycoside-sensitive mutations have been described in several ethnic groups, causing sudden deafness. We started similar studies in Mexican individuals, treated or not with an aminoglycoside, to determine whether similar alterations could be detected. To date in over 60 individuals analyzed we found only one case of polymorphism in a streptomycin treated patient. We developed a simple method to identify such mitochondrial gene in a larger population to make recommendations to use an alternative treatment which do not cause ototoxicity in the mutation bearing patient.
{"title":"Aminoglycosides: therapeutics, ototoxicity and hypersensitivity of mitochondrial genetic origin.","authors":"N M Torres-Ruíz, O Granados, G Meza","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Aminoglycosides such as streptomycin or gentamycin are employed to treat stubborn infections. In México, tuberculosis patients are successfully treated with 1 g/day for over 6 months. Ototoxicity is often seen as a consequence of prolonged treatment with aminoglycosides. In young people STP damages the vestibule of the ear; in elder patients it diminishes hearing and balance. These effects are due to streptidine, a metabolite of STP produced in elder patients and detected in blood by liquid chromatography. On occasion, sudden deafness is established after only a short treatment period as the result of the presence of a single nucleotide mutation in the mitochondrial 12S rRNA gene. In patients with this polymorphism, aminoglycosides produce a stereotypic conformation similar to the bacterial 16S rRNA thus inhibiting the synthesis of proteins. Many aminoglycoside-sensitive mutations have been described in several ethnic groups, causing sudden deafness. We started similar studies in Mexican individuals, treated or not with an aminoglycoside, to determine whether similar alterations could be detected. To date in over 60 individuals analyzed we found only one case of polymorphism in a streptomycin treated patient. We developed a simple method to identify such mitochondrial gene in a larger population to make recommendations to use an alternative treatment which do not cause ototoxicity in the mutation bearing patient.</p>","PeriodicalId":20701,"journal":{"name":"Proceedings of the Western Pharmacology Society","volume":"54 ","pages":"49-51"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30507699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C Izazola-Conde, D Zamora-de la Cruz, G Tenorio-Guajardo
Information related to adverse drug effects caused by ocular medications and ocular adverse effects of systemically administered drugs has increased over the last several decades. Here we review the medical literature over the last four decades to both quantitatively and qualitatively determine the adverse effects of ocular drugs and ocular toxicity of non-ocular drugs. A systematic bibliographic review of the literature was performed with the following terms: "drug treatment", "drug therapy", "ocular adverse effects", "ocular side effects", "ocular toxicity", "systemic side effects", "systemic adverse effects", "systemic toxicity", "ocular drug" and "ophthalmic drug" using the Boolean operators or, and, not. Searches focused on: (1) Ocular side/adverse effects of ophthalmic drugs; (2) Ocular side/adverse effects of systemic drugs; (3) Systemic side/adverse effects of ophthalmic drugs. PubMed was used to perform searches. Limits included: species, human and field tag, abstract/title, dates from 01/01/1971 to 31/12/2010. A sub-selection of references was made by discarding articles that were irrelevant for the topics listed above. Adverse effects of alpha2-adrenergic agonists, beta-adrenergic antagonists, quinine derivatives and antituberculosis agents appear in the literature throughout the period of the review. Adverse effects of newer drugs such as amiodarone, phosphodiesterase 5 inhibitors, antiepileptics, tamoxifen, and its interactions have been published principally in the last two decades. It is imperative for patient safety that knowledge of the adverse effects of drugs on the eye whether topically or systemically administered, and the possible systemic effects of drugs given as ophthalmic medications be emphasized to clinicians.
{"title":"Ocular and systemic adverse effects of ophthalmic and non ophthalmic medications.","authors":"C Izazola-Conde, D Zamora-de la Cruz, G Tenorio-Guajardo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Information related to adverse drug effects caused by ocular medications and ocular adverse effects of systemically administered drugs has increased over the last several decades. Here we review the medical literature over the last four decades to both quantitatively and qualitatively determine the adverse effects of ocular drugs and ocular toxicity of non-ocular drugs. A systematic bibliographic review of the literature was performed with the following terms: \"drug treatment\", \"drug therapy\", \"ocular adverse effects\", \"ocular side effects\", \"ocular toxicity\", \"systemic side effects\", \"systemic adverse effects\", \"systemic toxicity\", \"ocular drug\" and \"ophthalmic drug\" using the Boolean operators or, and, not. Searches focused on: (1) Ocular side/adverse effects of ophthalmic drugs; (2) Ocular side/adverse effects of systemic drugs; (3) Systemic side/adverse effects of ophthalmic drugs. PubMed was used to perform searches. Limits included: species, human and field tag, abstract/title, dates from 01/01/1971 to 31/12/2010. A sub-selection of references was made by discarding articles that were irrelevant for the topics listed above. Adverse effects of alpha2-adrenergic agonists, beta-adrenergic antagonists, quinine derivatives and antituberculosis agents appear in the literature throughout the period of the review. Adverse effects of newer drugs such as amiodarone, phosphodiesterase 5 inhibitors, antiepileptics, tamoxifen, and its interactions have been published principally in the last two decades. It is imperative for patient safety that knowledge of the adverse effects of drugs on the eye whether topically or systemically administered, and the possible systemic effects of drugs given as ophthalmic medications be emphasized to clinicians.</p>","PeriodicalId":20701,"journal":{"name":"Proceedings of the Western Pharmacology Society","volume":"54 ","pages":"69-72"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30507704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mario I Ortiz, Raúl Monroy-Maya, Marisela Soto-Ríos, Lourdes Cristina Carrillo-Alarcón, Héctor A Ponce-Monter, Eduardo Rangel-Flores, José J Loo-Estrada, Jeannett A Izquierdo-Vega, Manuel Sánchez-Gutiérrez
Tissue degeneration, infection, inflammation, cancer, trauma, surgery and limb fractures all produce pain. Each of these physiological abnormalities requires a therapeutic approach different from the last. In acute pain, caused by fracture, several classes of analgesics have been utilized. These basic remedies for analgesia, however, are still confined to a small number of medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), local anesthetics and opioids. In addition, most of these drugs have side effects, limiting their use in clinical practice. The purpose of this study was to compare the efficacy of three NSAIDs to relief acute pain caused by ankle fracture. Sixty subjects with ankle fracture were randomized to receive ketorolac, diclofenac, or etoricoxib, every 12 hours in a prospective, double-blind study. Forty-nine patients completed the study. The subjects' assessments of ankle pain on the visual analog scale and a Likert scale showed a significant reduction from baseline over 24 hr, regardless the treatment group. All treatments showed a similar profile in pain reduction. Etoricoxib, diclofenac and ketorolac twice daily are a rapid and effective treatment for acute pain. All the regimens were well tolerated in this study.
{"title":"Effectiveness of diclofenac, ketorolac and etoricoxib in the treatment of acute pain from ankle fracture.","authors":"Mario I Ortiz, Raúl Monroy-Maya, Marisela Soto-Ríos, Lourdes Cristina Carrillo-Alarcón, Héctor A Ponce-Monter, Eduardo Rangel-Flores, José J Loo-Estrada, Jeannett A Izquierdo-Vega, Manuel Sánchez-Gutiérrez","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tissue degeneration, infection, inflammation, cancer, trauma, surgery and limb fractures all produce pain. Each of these physiological abnormalities requires a therapeutic approach different from the last. In acute pain, caused by fracture, several classes of analgesics have been utilized. These basic remedies for analgesia, however, are still confined to a small number of medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), local anesthetics and opioids. In addition, most of these drugs have side effects, limiting their use in clinical practice. The purpose of this study was to compare the efficacy of three NSAIDs to relief acute pain caused by ankle fracture. Sixty subjects with ankle fracture were randomized to receive ketorolac, diclofenac, or etoricoxib, every 12 hours in a prospective, double-blind study. Forty-nine patients completed the study. The subjects' assessments of ankle pain on the visual analog scale and a Likert scale showed a significant reduction from baseline over 24 hr, regardless the treatment group. All treatments showed a similar profile in pain reduction. Etoricoxib, diclofenac and ketorolac twice daily are a rapid and effective treatment for acute pain. All the regimens were well tolerated in this study.</p>","PeriodicalId":20701,"journal":{"name":"Proceedings of the Western Pharmacology Society","volume":"53 ","pages":"46-8"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30291428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marco Antonio Mibielli, Carlos Pereira Nunes, José Carlos Cohen, Ari Boulanger Scussel, Rafael Higashi, Gabriel Gherman Bendavit, Lisa Oliveira, Mauro Geller
This randomized, controlled, double-blind clinical study in parallel groups evaluated the safety and efficacy of an oral combination diclofenac-cholestyramine, nucleotides (uridine and cytidine) and vitamin B12 versus the oral combination of nucleotides and vitamin B12 in the treatment of acute, non-traumatic pain. Subjects received twice-daily, 10-day oral administration of diclofenac-cholestyramine + uridine + cytidine + vitamin B12 (Group DN, n=40) or uridine + cytidine + vitamin B12 (Group NB, n=41). The primary study endpoint was the number of subjects with VAS reduction of >30mm after 10 days of treatment. Secondary endpoints included the number of patients with improvement >5 points in the Patient Functionality Questionnaire after 10 days of treatment, and the number of subjects presenting adverse events. Treatment with the combination of diclofenac-cholestyramine, nucleotides and Vitamin B12 resulted in a higher number of subjects with VAS score reductions >30mm after 10 days of treatment (87.5% subjects) than in the control group administered nucleotides and Vitamin B12 (51.23% of subjects), (p>0.0006). A significantly higher number of subjects in the DN group (80%) had a score reduction of >5 points in the Patient Functionality Questionnaire at after 10 days of treatment compared to Group NB (29.3%), (p<0.001). The number of subjects presenting AEs did not vary significantly between treatment groups (p=0.587). The combination of diclofenac-cholestyramine with uridine, cytidine and vitamin B12 was well-tolerated over a 10-day treatment period. The combination reduced pain and improved functionality among subjects presenting acute, non-traumatic pain in the lower back, hips, and neck.
{"title":"Treatment of acute, non-traumatic pain using a combination of diclofenac-cholestyramine, uridine triphosphate, cytidine monophosphate, and hydroxycobalamin.","authors":"Marco Antonio Mibielli, Carlos Pereira Nunes, José Carlos Cohen, Ari Boulanger Scussel, Rafael Higashi, Gabriel Gherman Bendavit, Lisa Oliveira, Mauro Geller","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This randomized, controlled, double-blind clinical study in parallel groups evaluated the safety and efficacy of an oral combination diclofenac-cholestyramine, nucleotides (uridine and cytidine) and vitamin B12 versus the oral combination of nucleotides and vitamin B12 in the treatment of acute, non-traumatic pain. Subjects received twice-daily, 10-day oral administration of diclofenac-cholestyramine + uridine + cytidine + vitamin B12 (Group DN, n=40) or uridine + cytidine + vitamin B12 (Group NB, n=41). The primary study endpoint was the number of subjects with VAS reduction of >30mm after 10 days of treatment. Secondary endpoints included the number of patients with improvement >5 points in the Patient Functionality Questionnaire after 10 days of treatment, and the number of subjects presenting adverse events. Treatment with the combination of diclofenac-cholestyramine, nucleotides and Vitamin B12 resulted in a higher number of subjects with VAS score reductions >30mm after 10 days of treatment (87.5% subjects) than in the control group administered nucleotides and Vitamin B12 (51.23% of subjects), (p>0.0006). A significantly higher number of subjects in the DN group (80%) had a score reduction of >5 points in the Patient Functionality Questionnaire at after 10 days of treatment compared to Group NB (29.3%), (p<0.001). The number of subjects presenting AEs did not vary significantly between treatment groups (p=0.587). The combination of diclofenac-cholestyramine with uridine, cytidine and vitamin B12 was well-tolerated over a 10-day treatment period. The combination reduced pain and improved functionality among subjects presenting acute, non-traumatic pain in the lower back, hips, and neck.</p>","PeriodicalId":20701,"journal":{"name":"Proceedings of the Western Pharmacology Society","volume":"53 ","pages":"5-12"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30292036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Enrique Gijón, Xaviera García, Miguel Angel Contreras-Barrios, Jaime Valencia, Gil Magos, Marte Lorenzana-Jiménez
Struthanthus venetus (Sv) from family Loranthaceae is employed in traditional medicine to treat coughs. In previous studies, a methanol extract of Sv shows hypotensive effects and changes in heart rate in rats. The purpose of this study was to determine the effect of a methanol extract of Sv on the electrocardiogram (EKG), and histological changes in the guinea pig heart. Male Hartley guinea pigs anesthetized with sodium pentobarbital received 50 mg/kg ip of Sv extract. An EKG was taken before and after the ip application of Sv extract. The EKG showed changes in QRS morphology, ST segment and T wave, Q wave in DI and AVL, data of ischemia, and myocardial injury. Guinea pigs were sacrificed after 1-93 days; the hearts were prepared for histopathological study with HE, PAS, Masson and Gallegos staining. The methanol extract of Sv causes apoptosis of myocardial fibers, degeneration of muscle fibers, staying only the fibro vascular skeleton, necrosis areas, hyperplasia of endothelial cells and mitotic figures in vascular endothelial cells and myocardial fibers. Changes in the EKG of the guinea pig could explain the hypotensive effects of Sv in rats. Sv extract causes cardio toxicity, apoptosis, autophagic and mitogenic activity in guinea pig heart, suggesting regeneration of the heart.
{"title":"Effects of Struthanthus venetus methanol extract in the guinea pig heart.","authors":"Enrique Gijón, Xaviera García, Miguel Angel Contreras-Barrios, Jaime Valencia, Gil Magos, Marte Lorenzana-Jiménez","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Struthanthus venetus (Sv) from family Loranthaceae is employed in traditional medicine to treat coughs. In previous studies, a methanol extract of Sv shows hypotensive effects and changes in heart rate in rats. The purpose of this study was to determine the effect of a methanol extract of Sv on the electrocardiogram (EKG), and histological changes in the guinea pig heart. Male Hartley guinea pigs anesthetized with sodium pentobarbital received 50 mg/kg ip of Sv extract. An EKG was taken before and after the ip application of Sv extract. The EKG showed changes in QRS morphology, ST segment and T wave, Q wave in DI and AVL, data of ischemia, and myocardial injury. Guinea pigs were sacrificed after 1-93 days; the hearts were prepared for histopathological study with HE, PAS, Masson and Gallegos staining. The methanol extract of Sv causes apoptosis of myocardial fibers, degeneration of muscle fibers, staying only the fibro vascular skeleton, necrosis areas, hyperplasia of endothelial cells and mitotic figures in vascular endothelial cells and myocardial fibers. Changes in the EKG of the guinea pig could explain the hypotensive effects of Sv in rats. Sv extract causes cardio toxicity, apoptosis, autophagic and mitogenic activity in guinea pig heart, suggesting regeneration of the heart.</p>","PeriodicalId":20701,"journal":{"name":"Proceedings of the Western Pharmacology Society","volume":"53 ","pages":"26-8"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30292040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mario I Ortiz, Ramón Estévez-Castillo, Martha M Bautista-Rivas, Georgina Romo-Hernández, Juan M López-Cadena, José A Copca-García
Persistent pulmonary hypertension of the newborn is defined as the failure of the normal circulatory transition that occurs after birth. It is a syndrome characterized by marked pulmonary hypertension that causes hypoxemia and right-to-left extra-pulmonary shunting of blood. In the treatment of persistent pulmonary hypertension of the newborn, the goal is to increase oxygen flow to the baby's organs to prevent serious health problems. Treatment may include medication, mechanical ventilation and respiratory therapy. We performed a retrospective, descriptive and transversal study to investigate the prevalence and treatment of neonatal patients with persistent pulmonary hypertension who were admitted at the Hospital del Niño DIF from 2004 to 2008. Data, collected from hospital charts, included demographic, clinical course and use of medication. A total of 38 patients were included (prevalence of 5.7%). The average age of patients was 8.4 +/- 1.4 days. The mortality rate was 42.1%. Data were collected and 45 different drugs were given to the pediatric patients. The median number of drugs/inpatient was 8.3 (1-18). The therapeutic class most prescribed was anti-infective (29.9% of all the prescriptions), followed by cardiovascular and renal drugs (26.4% of all the prescriptions) and gastrointestinal agents (14.6% of all the prescriptions). Ranitidine was the drug most commonly used, followed by ampicillin and midazolam. We found a high mortality rate and as in many studies, the therapeutic class most used were anti-infectives.
{"title":"Prevalence and treatment of persistent pulmonary hypertension in the newborn in a Mexican pediatric hospital.","authors":"Mario I Ortiz, Ramón Estévez-Castillo, Martha M Bautista-Rivas, Georgina Romo-Hernández, Juan M López-Cadena, José A Copca-García","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Persistent pulmonary hypertension of the newborn is defined as the failure of the normal circulatory transition that occurs after birth. It is a syndrome characterized by marked pulmonary hypertension that causes hypoxemia and right-to-left extra-pulmonary shunting of blood. In the treatment of persistent pulmonary hypertension of the newborn, the goal is to increase oxygen flow to the baby's organs to prevent serious health problems. Treatment may include medication, mechanical ventilation and respiratory therapy. We performed a retrospective, descriptive and transversal study to investigate the prevalence and treatment of neonatal patients with persistent pulmonary hypertension who were admitted at the Hospital del Niño DIF from 2004 to 2008. Data, collected from hospital charts, included demographic, clinical course and use of medication. A total of 38 patients were included (prevalence of 5.7%). The average age of patients was 8.4 +/- 1.4 days. The mortality rate was 42.1%. Data were collected and 45 different drugs were given to the pediatric patients. The median number of drugs/inpatient was 8.3 (1-18). The therapeutic class most prescribed was anti-infective (29.9% of all the prescriptions), followed by cardiovascular and renal drugs (26.4% of all the prescriptions) and gastrointestinal agents (14.6% of all the prescriptions). Ranitidine was the drug most commonly used, followed by ampicillin and midazolam. We found a high mortality rate and as in many studies, the therapeutic class most used were anti-infectives.</p>","PeriodicalId":20701,"journal":{"name":"Proceedings of the Western Pharmacology Society","volume":"53 ","pages":"39-41"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30291425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this study we present the efficacy of aspiration of disc material employing the Stryker Disc Dekompressor during percutaneous microdiscectomy for the treatment of chronic spinal and radicular pain due to contained lumber disc herniation and compare the short-term outcome in such patients with those who received lumber epidural injection. A total of 50 patients with chronic lumber discogenic pain and radiculopathy were enrolled in this study and were randomized into two groups. Group 1 (n=26) underwent first time, single-level lumber discectomy at either L3-4, L4-5, or L5-S1 using the Stryker Disc Dekompressor for aspiration of disc material and Group 2 (n=24) received epidural steroid/local anesthetic injection. Data on patient demographics, operative time, length of hospitalization, incidence of postoperative complications, analgesic usage and postoperative complications were obtained. For short-term evaluation of the outcome in the two patient groups, the Visual Analogue Scale (VAS) from 0-10 for back pain and radicular pain were obtained preoperatively, 24 hr and 1-6 wk postoperatively. Also, the straight leg raising test (SLRT) was performed and recorded. A significant decrease in the radicular pain scores and an increase in SLRT degrees with a decrease in the back pain scores was seen in the disc Dekompressor group with minimal incidence of postoperative complications. In the epidural injection group, the back pain scores were significantly decreased postoperatively while the radicular pain and the SLRT degrees were insignificantly changed 24 hr postoperatively and at wk 6. We conclud that when standardized patient selection criteria are used, the disc DeKompressor is a safe and more effective treatment for radicular pain of discogenic origin than epidural injection with steroid/local anesthetic. Back pain of discogenic origin was more effectively treated with the epidural steroid/local anesthetic injection. Treatment of patients with radicular pain associated with contained disc herniation using the Dekompressor can be a safe and more effective procedure.
{"title":"Percutaneous microdiscectomy versus epidural injection for management of chronic spinal pain.","authors":"Judith Aronsohn, Kenneth Chapman, Magdy Soliman, Trusha Shah, Sherif Costandi, Rafik Michael, Adel R Abadir","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In this study we present the efficacy of aspiration of disc material employing the Stryker Disc Dekompressor during percutaneous microdiscectomy for the treatment of chronic spinal and radicular pain due to contained lumber disc herniation and compare the short-term outcome in such patients with those who received lumber epidural injection. A total of 50 patients with chronic lumber discogenic pain and radiculopathy were enrolled in this study and were randomized into two groups. Group 1 (n=26) underwent first time, single-level lumber discectomy at either L3-4, L4-5, or L5-S1 using the Stryker Disc Dekompressor for aspiration of disc material and Group 2 (n=24) received epidural steroid/local anesthetic injection. Data on patient demographics, operative time, length of hospitalization, incidence of postoperative complications, analgesic usage and postoperative complications were obtained. For short-term evaluation of the outcome in the two patient groups, the Visual Analogue Scale (VAS) from 0-10 for back pain and radicular pain were obtained preoperatively, 24 hr and 1-6 wk postoperatively. Also, the straight leg raising test (SLRT) was performed and recorded. A significant decrease in the radicular pain scores and an increase in SLRT degrees with a decrease in the back pain scores was seen in the disc Dekompressor group with minimal incidence of postoperative complications. In the epidural injection group, the back pain scores were significantly decreased postoperatively while the radicular pain and the SLRT degrees were insignificantly changed 24 hr postoperatively and at wk 6. We conclud that when standardized patient selection criteria are used, the disc DeKompressor is a safe and more effective treatment for radicular pain of discogenic origin than epidural injection with steroid/local anesthetic. Back pain of discogenic origin was more effectively treated with the epidural steroid/local anesthetic injection. Treatment of patients with radicular pain associated with contained disc herniation using the Dekompressor can be a safe and more effective procedure.</p>","PeriodicalId":20701,"journal":{"name":"Proceedings of the Western Pharmacology Society","volume":"53 ","pages":"16-9"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30292038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mario I Ortiz, Ildefonsa Hernández-Rubio, Deyanira Cortés-Alva, Georgina Romo-Hernández, Juan M López-Cadena, José A Copca-García
Acute leukemia is the most common malignancy in children, and accounts for nearly 35% of all childhood cancers. Acute myelogenous leukemia (AML) constitutes about 20% of acute leukemias. Initially, treatment of AML involves the immediate management of emergencies associated as hyperleukocytosis, tumor lysis syndrome, hemorrhages and infections. Therefore we performed a retrospective, descriptive and transversal study to investigate the drugs used in patients with AML who were admitted at the Hospital del Niño DIF from 2007 to 2008. Data were collected from hospital. The data included demographic, clinical data and drug usage. A total of 13 patients (12 male and 1 female) were included (prevalence of 16.5% among all cancers in the hospital). The mean age of patients was 6.2 +/- 4.6 years. The mortality rate was 30.8%. Twelve different drugs were given to the patients (10 antineoplastic agents, ondansetron and folinic acid). The median number of drugs/inpatient was 5.4 (range 3-9). Four-hundred thirty-one doses of antineoplastic drugs were administered in 409 sessions. The most used were cytarabine (55.9 %), followed by doxorubicin (7.2 %) and vincristine (6.7 %). Three-hundred twenty-four doses of ondansetron were administered in 409 sessions. We conclude that AML is common in our hospital with a high mortality rate. Also, the antineoplastic agent most used was the pyrimidine analogue cytarabine.
{"title":"Treatment of acute myelogenous leukemia in a Mexican pediatric hospital.","authors":"Mario I Ortiz, Ildefonsa Hernández-Rubio, Deyanira Cortés-Alva, Georgina Romo-Hernández, Juan M López-Cadena, José A Copca-García","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Acute leukemia is the most common malignancy in children, and accounts for nearly 35% of all childhood cancers. Acute myelogenous leukemia (AML) constitutes about 20% of acute leukemias. Initially, treatment of AML involves the immediate management of emergencies associated as hyperleukocytosis, tumor lysis syndrome, hemorrhages and infections. Therefore we performed a retrospective, descriptive and transversal study to investigate the drugs used in patients with AML who were admitted at the Hospital del Niño DIF from 2007 to 2008. Data were collected from hospital. The data included demographic, clinical data and drug usage. A total of 13 patients (12 male and 1 female) were included (prevalence of 16.5% among all cancers in the hospital). The mean age of patients was 6.2 +/- 4.6 years. The mortality rate was 30.8%. Twelve different drugs were given to the patients (10 antineoplastic agents, ondansetron and folinic acid). The median number of drugs/inpatient was 5.4 (range 3-9). Four-hundred thirty-one doses of antineoplastic drugs were administered in 409 sessions. The most used were cytarabine (55.9 %), followed by doxorubicin (7.2 %) and vincristine (6.7 %). Three-hundred twenty-four doses of ondansetron were administered in 409 sessions. We conclude that AML is common in our hospital with a high mortality rate. Also, the antineoplastic agent most used was the pyrimidine analogue cytarabine.</p>","PeriodicalId":20701,"journal":{"name":"Proceedings of the Western Pharmacology Society","volume":"53 ","pages":"37-8"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30291424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mario I Ortiz, Héctor A Ponce-Monter, Eduardo Fernández-Martínez, Arturo Macías, Jeannett A Izquierdo-Vega, Manuel Sánchez-Gutiérrez, Lourdes Cristina Carrillo-Alarcón, Eduardo Rangel-Flores, José F Saavedra-Ramírez
Pharmacovigilance is the permanent collection and assessment of the safety data of drugs in the interest of precise knowledge of the safety profile. We monitored notifications of suspected adverse reactions (AR) produced by psychoactive medications (ARPM) in a Psychiatry Hospital, during a 4-month period. Yellow cards for adverse reaction reporting were distributed to the medical personal at the Hospital Psiquiátrico Villa Ocaranza, Pachuca Hidalgo, Mexico. For each notification, the ARPM was analyzed in order to verify causality. One hundred twelve hospitalized patients entered the study (44 male and 68 female). The mean +/- SD age of the patients was 46 +/- 4.5 years. The major diagnoses found were: schizophrenia (35.7%), severe mental retardation (17 %), moderate mental retardation (MMR)/epilepsy (12.5%), MMR (8.03%), and others (26.7%). During the study there were 721 therapeutic regimens prescribed to patients on psychiatric service. Patients were receiving an average of 5.3 +/- 1.1 (range 4 to 8) psychiatric medications. The psychiatrists reported only 5 ARPMs in five patients (prevalence: 4.46%). Among the drugs involved were neuroleptics (47.8%), antiepileptic (39.1%), and others (13.04%). The organs and systems affected by the ARs were the central nervous system, skin, endocrinological and gastrointestinal. A causal association between the medication and the AR were classified as probable in three cases, as possible in one case, as doubtful in one case and as definite in no case.
药物警戒是对药物安全性数据的永久收集和评估,目的是准确了解其安全性概况。在4个月的时间里,我们对一家精神病院的精神活性药物(ARPM)产生的疑似不良反应(AR)通报进行了监测。向墨西哥帕丘卡伊达尔戈Psiquiátrico Villa Ocaranza医院的医务人员分发了报告不良反应的黄牌。对于每个通知,分析ARPM以验证因果关系。112名住院患者进入研究(男性44名,女性68名)。患者平均+/- SD年龄为46 +/- 4.5岁。主要诊断为:精神分裂症(35.7%)、重度智力迟钝(17%)、中度智力迟钝(MMR)/癫痫(12.5%)、MMR(8.03%)和其他(26.7%)。在研究期间,有721种治疗方案被开给精神病患者。患者平均接受5.3 +/- 1.1(范围4 - 8)精神药物治疗。精神科医生在5名患者中仅报告了5例arpm(患病率:4.46%)。其中抗精神病药占47.8%,抗癫痫药占39.1%,其他占13.04%。受ARs影响的器官和系统包括中枢神经系统、皮肤、内分泌和胃肠道。药物与AR之间的因果关系在三例中被分类为可能,在一例中被分类为可能,在一例中被分类为可疑,在没有病例中被分类为明确。
{"title":"Pharmacovigilance of psychoactive medications in a Mexican psychiatric hospital.","authors":"Mario I Ortiz, Héctor A Ponce-Monter, Eduardo Fernández-Martínez, Arturo Macías, Jeannett A Izquierdo-Vega, Manuel Sánchez-Gutiérrez, Lourdes Cristina Carrillo-Alarcón, Eduardo Rangel-Flores, José F Saavedra-Ramírez","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Pharmacovigilance is the permanent collection and assessment of the safety data of drugs in the interest of precise knowledge of the safety profile. We monitored notifications of suspected adverse reactions (AR) produced by psychoactive medications (ARPM) in a Psychiatry Hospital, during a 4-month period. Yellow cards for adverse reaction reporting were distributed to the medical personal at the Hospital Psiquiátrico Villa Ocaranza, Pachuca Hidalgo, Mexico. For each notification, the ARPM was analyzed in order to verify causality. One hundred twelve hospitalized patients entered the study (44 male and 68 female). The mean +/- SD age of the patients was 46 +/- 4.5 years. The major diagnoses found were: schizophrenia (35.7%), severe mental retardation (17 %), moderate mental retardation (MMR)/epilepsy (12.5%), MMR (8.03%), and others (26.7%). During the study there were 721 therapeutic regimens prescribed to patients on psychiatric service. Patients were receiving an average of 5.3 +/- 1.1 (range 4 to 8) psychiatric medications. The psychiatrists reported only 5 ARPMs in five patients (prevalence: 4.46%). Among the drugs involved were neuroleptics (47.8%), antiepileptic (39.1%), and others (13.04%). The organs and systems affected by the ARs were the central nervous system, skin, endocrinological and gastrointestinal. A causal association between the medication and the AR were classified as probable in three cases, as possible in one case, as doubtful in one case and as definite in no case.</p>","PeriodicalId":20701,"journal":{"name":"Proceedings of the Western Pharmacology Society","volume":"53 ","pages":"44-5"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30291427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
José F Rivas-Vilchis, Fernando Hernández Sánchez, Rodolfo Velasco Lezama
Calorimetry is an analytical method that measures heat flow between a heat source and sample. The sample gains or losses heat based on physical or chemical composition. Differential scanning calorimetry (DSC) compares the results of heating a sample to those for heating a reference material. DSC then measures internal energy or a sample's calorific capacity. The aim of this study was to examine the thermal characteristics of platelet activation. Blood was obtained from human volunteers by venipuncture and collected in 5 ml siliconised and citronated vacutainer tubes. Platelet counts were measured using a hemocytometer. Platelet-rich (PRP) or platelet-poor plasma (PPP) was obtained by centrifugation. Ten microliters of PRP or PPP were placed into aluminum pans for DSC with or without activation by epinephrine (5.0 microM) or CaCl2 (50 microM). To avoid a spontaneous activation of platelets samples were kept frozen, after a 5 min period of stabilization, 5 microl of aggregation-inducing agent was added. Scans were initiated at a -12 degrees C after stabilization, with an increase of a 5 degrees C/min to a maximum of 60 degrees C. The experiments were performed on a TA Differential Scanning Calorimeter (New Castle, DE, USA). The difference in heat evolved between the PRP and PPP during the process of platelet activation was 253 J/g. The difference of heat flow in the activation of PRP versus PPP may correspond to an exothermic process involved in platelet aggregation.
量热法是一种测量热源和样品之间热流的分析方法。样品根据其物理或化学组成获得或损失热量。差示扫描量热法(DSC)将加热样品的结果与加热参考物质的结果进行比较。DSC然后测量内能或样品的热容量。本研究的目的是研究血小板活化的热特性。通过静脉穿刺从人类志愿者身上获得血液,并在5ml硅化和柠檬酸化真空管中收集。血小板计数用血细胞计测定。离心获得富血小板血浆(PRP)或贫血小板血浆(PPP)。将10微升的PRP或PPP放入铝锅中,用肾上腺素(5.0微米)或CaCl2(50微米)激活或不激活进行DSC。为了避免血小板自发活化,将样品冷冻保存,稳定5分钟后,加入5微升凝集诱导剂。稳定后在-12℃下开始扫描,增加5℃/min至最高60℃。实验在TA差示扫描量热计(New Castle, DE, USA)上进行。在血小板活化过程中,PRP和PPP的热演化差异为253 J/g。PRP与PPP激活的热流差异可能对应于血小板聚集的放热过程。
{"title":"Thermal analysis of platelet aggregation assessed by differential scanning calorimetry.","authors":"José F Rivas-Vilchis, Fernando Hernández Sánchez, Rodolfo Velasco Lezama","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Calorimetry is an analytical method that measures heat flow between a heat source and sample. The sample gains or losses heat based on physical or chemical composition. Differential scanning calorimetry (DSC) compares the results of heating a sample to those for heating a reference material. DSC then measures internal energy or a sample's calorific capacity. The aim of this study was to examine the thermal characteristics of platelet activation. Blood was obtained from human volunteers by venipuncture and collected in 5 ml siliconised and citronated vacutainer tubes. Platelet counts were measured using a hemocytometer. Platelet-rich (PRP) or platelet-poor plasma (PPP) was obtained by centrifugation. Ten microliters of PRP or PPP were placed into aluminum pans for DSC with or without activation by epinephrine (5.0 microM) or CaCl2 (50 microM). To avoid a spontaneous activation of platelets samples were kept frozen, after a 5 min period of stabilization, 5 microl of aggregation-inducing agent was added. Scans were initiated at a -12 degrees C after stabilization, with an increase of a 5 degrees C/min to a maximum of 60 degrees C. The experiments were performed on a TA Differential Scanning Calorimeter (New Castle, DE, USA). The difference in heat evolved between the PRP and PPP during the process of platelet activation was 253 J/g. The difference of heat flow in the activation of PRP versus PPP may correspond to an exothermic process involved in platelet aggregation.</p>","PeriodicalId":20701,"journal":{"name":"Proceedings of the Western Pharmacology Society","volume":"53 ","pages":"13-5"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30292037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}